Remodulin Phase IV Trials On Dosing, Duration Of Effect, Suggested by Cmte
Executive Summary
FDA approval of United Therapeutics' Remodulin (treprostinil) should include Phase IV commitments examining duration of effect and proper dosing range, FDA's Cardiovascular & Renal Drugs Advisory Committee said during its Aug. 9 review of the pulmonary arterial hypertension therapy.